Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gemma

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2012
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)A Inoue, K Kobayashi, M Maemondo, et al.
Nihon Ika Daigaku Zasshi|January 20, 1999
[A case of adenocarcinoma of the lung presenting ground glass opacity detected by spiral CT in lung cancer screening]K Yamamoto, M Andoh, K Uematsu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2015
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902S Sugawara, S Oizumi, K Minato, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 1996
[Phase I study on DMDC]A Gemma, S Kudoh, M Fukuoka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trialK Kubota, H Sakai, N Katakami, et al.
Cancer Research|July 4, 1998
Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancerL Burke, M A Khan, A N Freedman, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2012
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)A Inoue, K Kobayashi, M Maemondo, et al.
Nihon Ika Daigaku Zasshi|January 20, 1999
[A case of adenocarcinoma of the lung presenting ground glass opacity detected by spiral CT in lung cancer screening]K Yamamoto, M Andoh, K Uematsu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2015
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902S Sugawara, S Oizumi, K Minato, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 1996
[Phase I study on DMDC]A Gemma, S Kudoh, M Fukuoka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trialK Kubota, H Sakai, N Katakami, et al.
Cancer Research|July 4, 1998
Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancerL Burke, M A Khan, A N Freedman, et al.
Pageof 9